{"gene":"SOX2","run_date":"2026-06-10T07:46:38","timeline":{"discoveries":[{"year":2020,"finding":"Cryo-EM structures of SOX2 HMG domain bound to nucleosomes show that SOX2 binds and locally distorts nucleosomal DNA at superhelical location 2, facilitates detachment of terminal nucleosomal DNA from the histone octamer to increase DNA accessibility, and repositions the N-terminal tail of histone H4 (including K16), suggesting incompatibility with higher-order nucleosome stacking.","method":"Cryo-electron microscopy structure determination","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — cryo-EM structures with functional validation of pioneer factor mechanism, published in high-impact journal with multiple structural observations","pmids":["32350470"],"is_preprint":false},{"year":2020,"finding":"Cryo-EM structures of OCT4-SOX2 bound to nucleosomes at two preferred positions show that OCT4-SOX2 differentially distort nucleosomal DNA depending on motif location; at one position, OCT4-SOX2 removes DNA from histone H2A and H3, while at an inverted motif only local DNA distortions are induced. OCT4 uses one of its two DNA-binding domains to engage DNA in both structures.","method":"Cryo-electron microscopy structure determination with base-pair resolution in vitro TF engagement mapping","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 / Strong — cryo-EM structures at two positions with base-pair resolution binding data, multiple orthogonal methods in single rigorous study","pmids":["32327602"],"is_preprint":false},{"year":2020,"finding":"SOX2 directly binds RNA through its HMG DNA-binding domain in vitro with high affinity, primarily interacting with double-stranded RNA in a non-sequence-specific fashion. In mouse embryonic stem cells, UV-crosslinked immunoprecipitation (CLIP) confirmed direct SOX2-RNA binding in vivo, identifying over a thousand SOX2-RNA interactions by fRIP-seq.","method":"In vitro binding assays, UV-crosslinked immunoprecipitation (CLIP), fRIP-seq","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct in vitro binding with domain mapping plus orthogonal in vivo CLIP, multiple methods in one study","pmids":["32286318"],"is_preprint":false},{"year":2020,"finding":"SOX2 binds RNA via a 60-amino-acid RNA-binding motif (RBM) positioned C-terminally of the HMG box, forming ternary RNA/SOX2/DNA complexes. Deletion of the RBM does not affect target gene selection but reduces binding to pluripotency-related transcripts, alters exon usage, and impairs reprogramming of somatic cells to pluripotency.","method":"In vitro binding assays, domain deletion mutagenesis, reprogramming efficiency assays, RNA binding assays in mouse and human cells","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — domain mutagenesis combined with functional reprogramming assays and binding experiments, multiple orthogonal methods","pmids":["32016422"],"is_preprint":false},{"year":2015,"finding":"SOX2 antagonizes the Hippo pathway to maintain cancer stem cells in osteosarcomas by directly repressing two Hippo activators, NF2 (Merlin) and WWC1 (Kibra), leading to exaggerated YAP function. This SOX2-Hippo axis is conserved in glioblastomas.","method":"ChIP, luciferase reporter assays, siRNA knockdown, tumor growth assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct promoter binding by ChIP combined with functional knockdown and rescue experiments, replicated across cancer types","pmids":["25832504"],"is_preprint":false},{"year":2014,"finding":"In squamous cell carcinomas (SCCs), SOX2 preferentially interacts with the transcription factor p63 (rather than OCT4 as in ES cells), and SOX2-p63 co-occupy a large number of genomic loci. SOX2 and p63 jointly regulate gene expression including the oncogene ETV4, which is essential for SOX2-amplified SCC cell survival.","method":"ChIP-seq, co-immunoprecipitation, gene expression analysis, siRNA knockdown","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide ChIP-seq plus functional validation, demonstrates context-dependent partner switching from OCT4 to p63","pmids":["24590290"],"is_preprint":false},{"year":2018,"finding":"CDK1 physically interacts with SOX2 and promotes its nuclear localization, phosphorylation, and transcriptional activity. Blockade or knockdown of CDK1 reduces phosphorylation, nuclear localization, and transcriptional activity of SOX2, and CDK1-driven tumor-initiating capacity is substantially reduced by SOX2 knockout.","method":"Proteomic co-immunoprecipitation, pharmacologic CDK1 inhibition, CRISPR knockout, spheroid and xenograft assays","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP plus multiple functional assays including KO rescue, single lab but orthogonal methods","pmids":["30297536"],"is_preprint":false},{"year":2018,"finding":"The ubiquitin-conjugating enzyme UBE2S mediates K11-linked polyubiquitin chain formation at SOX2-K123, marking SOX2 for proteasomal degradation. UBE2S fine-tunes SOX2 protein levels and reinforces ES cell self-renewal while repressing SOX2-mediated neural ectodermal differentiation.","method":"Ubiquitination assays, site-directed mutagenesis (K123 residue), proteasome inhibition, ES cell differentiation assays","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — identified specific ubiquitination site by mutagenesis plus functional consequences in ES cells, single lab with multiple orthogonal methods","pmids":["26292759"],"is_preprint":false},{"year":2018,"finding":"The E3 ubiquitin ligase complex CUL4A-DET1-COP1 ubiquitylates SOX2 (with COP1 as the substrate receptor interacting directly with SOX2) to promote its degradation, while the deubiquitylase OTUD7B removes polyubiquitin chains from SOX2 to stabilize it. These opposing enzymes govern SOX2 protein stability during neural progenitor cell differentiation.","method":"Co-immunoprecipitation, ubiquitination assays, siRNA knockdown, western blot during NPC differentiation","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct binding shown by co-IP plus opposing functional knockdowns with differentiation phenotype, multiple orthogonal methods in single lab","pmids":["30405104"],"is_preprint":false},{"year":2015,"finding":"AKT physically interacts with SOX2 protein and modulates its subcellular distribution. AKT kinase inhibition results in enhanced cytoplasmic retention of SOX2 (presumably via impaired nuclear import) and successive cytoplasmic proteasomal degradation. Ectopic SOX2 expression restores clonogenicity and tumorigenicity of AKT-inhibited cells.","method":"Co-immunoprecipitation, subcellular fractionation, pharmacologic AKT inhibition, rescue overexpression experiments, xenograft assays","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus localization and functional rescue, single lab with orthogonal methods","pmids":["26498353"],"is_preprint":false},{"year":2006,"finding":"SOX2 forms a complex with Oct-1 (encoded by Pou2f1) at specific DNA-binding sites to cooperatively transactivate the Pax6 lens ectoderm enhancer. Genetic combination of Sox2 and Pou2f1 mutant alleles causes impaired lens placode induction and complete failure of nasal placode induction in mice.","method":"Genetic epistasis (double mutant mice), in vitro transactivation assays, transgenic mouse enhancer assays","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis in mice combined with in vitro transactivation and transgenic enhancer validation, multiple orthogonal methods","pmids":["17140559"],"is_preprint":false},{"year":2020,"finding":"Sox2 interacts with the reprogramming barrier factor Ddx5 and inhibits the resolvase activity of Ddx5 on R-loops, thereby facilitating somatic cell reprogramming. Sox2, but not other Yamanaka factors, overcomes the inhibitory effects of RNaseH1 activity loss on reprogramming.","method":"Co-immunoprecipitation, R-loop profiling, reprogramming efficiency assays with RNaseH1 depletion/inactivation","journal":"Science advances","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus functional reprogramming assays, single lab with multiple orthogonal approaches","pmids":["32704541"],"is_preprint":false},{"year":2017,"finding":"SOX2 acts as a transcriptional activator during reprogramming: substituting SOX2-VP16 for wild-type SOX2 increased reprogramming efficiency and rate, whereas SOX2-HP1 (a repressor fusion) eliminated reprogramming. At early reprogramming stages, DNA-bound SOX2 was embedded in putative enhancers, about half of which were created de novo.","method":"Domain swap (VP16/HP1 fusions), reprogramming efficiency assays, ChIP-seq","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — activation domain substitution mutagenesis with functional reprogramming outcome plus ChIP-seq, clear mechanistic conclusion","pmids":["28813671"],"is_preprint":false},{"year":2019,"finding":"SOX2 directly represses NF2 and WWC1 in esophageal squamous cell carcinoma, activating YAP1. Multiple SOX2 binding peaks at the WWC1 locus and inverse correlation between SOX2 and WWC1 expression were found, and SOX2 gain-of-function promoted nuclear YAP1 expression while SOX2 silencing inhibited YAP1 activation.","method":"ChIP-seq, gene expression analysis, SOX2 overexpression/knockdown, YAP1 localization assays","journal":"Cancer medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq binding plus gain/loss-of-function functional experiments, single lab","pmids":["31560173"],"is_preprint":false},{"year":2016,"finding":"Sox2 loss in gastric epithelial cells enhances tumor formation in Apc-deficient gastric cells by inducing Tcf/Lef-dependent transcription and upregulating intestinal metaplasia-associated genes, identifying Sox2 as a context-dependent tumor suppressor in the stomach that restrains Wnt-driven adenoma formation.","method":"ChIP-seq, conditional Sox2 knockout mice, Apc/Wnt-driven tumor model, luciferase reporter assays","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO in vivo tumor model plus ChIP-seq and reporter assays, mechanistic pathway placement via Wnt/Tcf/Lef","pmids":["27498859"],"is_preprint":false},{"year":2011,"finding":"SOX2 knockdown in melanoma cells with high constitutive SOX2 expression resulted in 4.5-fold decreased invasiveness in vitro, associated with 87.8% reduction in MMP-3 mRNA. Conversely, SOX2 overexpression increased invasiveness 3.8-fold. MMP-3 knockdown inhibited invasion similarly but to a lesser degree than SOX2 knockdown.","method":"siRNA knockdown, overexpression, in vitro invasion assay, RT-PCR array of 84 invasion-related genes","journal":"Laboratory investigation","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — bidirectional manipulation (KD and OE) with defined downstream mediator (MMP-3), single lab","pmids":["22184093"],"is_preprint":false},{"year":2019,"finding":"Squamous lineage transcription factors p63 and SOX2 transactivate the intronic enhancer cluster of SLC2A1 (GLUT1), driving exceptional glucose influx in squamous cell carcinomas. Elevated glucose influx fuels NADPH/GSH generation and heightens anti-oxidative capacity in SCC tumors.","method":"ChIP-seq, luciferase reporter assays for enhancer transactivation, metabolic assays (NADPH/GSH measurement), pharmacologic glucose restriction","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq binding at SLC2A1 enhancer plus functional metabolic phenotype, single lab","pmids":["31412252"],"is_preprint":false},{"year":2020,"finding":"TRIM24 activates Sox2 expression at the transcriptional level in glioblastoma cells, as demonstrated by chromatin immunoprecipitation, reporter gene assay, and rescue experiments showing that TRIM24 participation in GBM infiltrative dissemination depends on Sox2.","method":"Chromatin immunoprecipitation, reporter gene assay, TRIM24 knockdown, Sox2 rescue experiments, xenotransplantation","journal":"Neuro-oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter assay and functional rescue, single lab with multiple orthogonal methods","pmids":["32492707"],"is_preprint":false},{"year":2021,"finding":"Oncogenic Sox2 in esophageal squamous cell carcinoma acquires new binding sites when partnered with Klf5, enhances activity of oncogenes such as Stat3, and activates endogenous retroviruses, inducing expression of double-stranded RNA and dependence on the RNA editing enzyme ADAR1.","method":"Sox2 ChIP-seq in murine esophageal organoids, epigenetic landscape mapping, ATAC-seq, transgenic carcinoma models","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — comprehensive ChIP-seq + epigenetic + functional analyses in isogenic organoid model spanning normal to cancer, multiple orthogonal methods","pmids":["33972779"],"is_preprint":false},{"year":2019,"finding":"Sox2 and Klf4 are a functional core for pluripotency induction: polycistronic expression of Sox2 and Klf4 alone (without exogenous Oct4) was sufficient to reprogram fibroblasts and neural progenitor cells to iPSCs. Sox2 and Klf4 cooperatively bind across the genome, leading to epigenetic remodeling of pluripotency genes, with stoichiometry of the two factors being essential.","method":"iPSC reprogramming assays, ChIP-seq, epigenetic analysis, genome-wide co-binding","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Moderate — functional reprogramming with ChIP-seq genome-wide co-binding, clear epistasis placing Sox2-Klf4 as core; single lab with multiple orthogonal methods","pmids":["31722212"],"is_preprint":false},{"year":2023,"finding":"In mouse E3.5 inner cell mass, SOX2 occupies preaccessible enhancers (opened by early TFs TFAP2C and NR5A2) rather than opening global enhancers, then widely redistributes to open new enhancers or poise them for future activation as cells adopt naive and formative pluripotency states.","method":"SOX2 ChIP-seq in mouse embryos from E3.5 to E7.5, ATAC-seq, genetic ablation","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide binding mapped in vivo in embryos across developmental stages with chromatin accessibility, multiple methods","pmids":["38096290"],"is_preprint":false},{"year":2023,"finding":"In mouse ES cells, two DNase I hypersensitive sites (DHSs) in the distal Sox2 enhancer cluster are each individually sufficient for long-range activation of Sox2 expression, requiring only a handful of key TF recognition sequences. Three nearby DHSs are context-dependent, showing no activity alone but augmenting the activity of the autonomous DHSs.","method":"Large-scale endogenous locus engineering (Big-IN), scarless DHS deletions/rearrangements/inversions, surgical TF motif alterations, multiple mESC clone analysis","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct endogenous locus manipulation with multiple independent clones, multiple structural perturbations with defined readouts","pmids":["36931273"],"is_preprint":false},{"year":2023,"finding":"Acute depletion of SOX2 results in rapid loss of thousands of accessible chromatin sites within one hour, demonstrating SOX2's role as a pioneer factor maintaining chromatin accessibility. Open chromatin sites maintained by SOX2 are highly predictive of gene expression, while other SOX2 binding sites are largely dispensable for gene regulation.","method":"Acute protein depletion, ATAC-seq, nascent transcription analysis, CRISPR-Cas9 regulatory element validation at Klf2 locus","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Moderate — acute depletion with rapid chromatin dynamics plus nascent transcription and CRISPR validation, multiple orthogonal methods in single study","pmids":["37691488"],"is_preprint":false},{"year":2024,"finding":"DNA and nucleosome binding by SOX2 induces major rearrangements in the conformational ensemble of SOX2's intrinsically disordered C-terminal region (IDR), redistributing interdomain interactions and variably exposing two activation domains critical for transcription. The IDR dynamics are guided by weak and dynamic charge interactions with the folded HMG DNA-binding domain.","method":"Single-molecule FRET, NMR spectroscopy, molecular simulations","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — single-molecule FRET and NMR with molecular simulations revealing structural mechanism, multiple orthogonal biophysical methods in single study","pmids":["38365983"],"is_preprint":false},{"year":2019,"finding":"Small endogenous fluctuations of SOX2 and OCT4 protein levels in G1 (but not S phase) bias ES cell fate commitment. High OCT4 levels increased chromatin accessibility at differentiation-associated enhancers as measured by ATAC-seq on cells gated for different endogenous factor levels.","method":"Knock-in reporter fusion ES cell lines, FACS-gated ATAC-seq, directed differentiation assays","journal":"Molecular systems biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — endogenous reporters with ATAC-seq at defined protein levels, single lab with orthogonal methods","pmids":["31556488"],"is_preprint":false},{"year":2010,"finding":"Sox2 activated proliferation of respiratory epithelial cells in vivo, associated with increased cyclin D1, and activated transcription of FoxM1 in vitro. Sox2 also induced ectopic differentiation of alveolar epithelial cells to those with morphologic and molecular characteristics of conducting airway epithelium.","method":"Conditional transgenic mouse overexpression, cell cycle gene expression analysis, in vitro transcription assays","journal":"American journal of respiratory cell and molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional in vivo overexpression with defined phenotypic and molecular readouts plus in vitro transcription assay, single lab","pmids":["20855650"],"is_preprint":false},{"year":2017,"finding":"SOX2 is required for inner ear neurogenesis: conditional SOX2 deletion at otocyst stages caused near-absence of NEUROG1-expressing neuroblasts, increased cell death in the neurosensory epithelium, and significantly reduced cochleovestibular ganglion volume. Heterozygotes showed milder neurogenesis reduction, indicating SOX2 dosage-dependence.","method":"Conditional knockout mice (Cre-lox), immunofluorescence, fate-mapping experiments","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 / Moderate — conditional KO in vivo with defined cellular and molecular phenotypes including NEUROG1 expression, dosage relationship confirmed in heterozygotes","pmids":["28642583"],"is_preprint":false},{"year":2020,"finding":"Sox2 directly controls fibronectin fibrillogenesis in Schwann cells, providing a highly oriented fibronectin matrix that supports their organization and directional migration. Sox2 also regulates extracellular matrix and migration genes and formation of focal adhesions, and Sox2-dependent fibronectin matrix is required for neuron migration along oriented Schwann cells.","method":"Sox2 overexpression/knockdown in RSC96 line, fibronectin matrix imaging, migration assays, co-culture with neurons, in vivo sciatic nerve regeneration","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — loss/gain-of-function with defined matrix and migration readouts, validated in vivo, single lab","pmids":["32029747"],"is_preprint":false},{"year":2014,"finding":"Conditional deletion of Sox2 from nascent cholinergic amacrine cells in the retina perturbed the normal ratio of cells in the ganglion cell layer versus inner nuclear layer and induced a bistratifying morphology with dendrites distributed to both ON and OFF strata.","method":"Conditional knockout mice (Cre-lox), quantitative cell counting, morphological analysis","journal":"The Journal of neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with specific cellular phenotype readout (layer positioning and dendritic stratification), single lab","pmids":["25057212"],"is_preprint":false},{"year":2017,"finding":"SOX2 ablation in dermal papilla (DP) cells of hair follicles causes a phenotypic switch from eumelanin to pheomelanin production. Mechanistically, Sox2 directly regulates Agouti (temporal upregulation) and Corin (downregulation) in DP, and BMP signaling regulation by Sox2 downregulates MC1R, Dct, and Tyr in melanocytes.","method":"Conditional Sox2 knockout in DP using Lepr-Cre, pigmentation analysis, gene expression, BMP signaling assays","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with defined molecular pathway (Sox2→Agouti/Corin→BMP→melanocyte genes), single lab","pmids":["35858560"],"is_preprint":false},{"year":2019,"finding":"In esophageal squamous cell carcinoma, elevated Sox2 signaling causes endothelial-mesenchymal transitions (EndMTs) by interacting with JMJD5, inducing EndMTs in cerebral endothelial cells. EC-specific suppression of Sox2 normalized endothelial differentiation and lumen formation, improving cerebral AVMs.","method":"Conditional Sox2 overexpression/suppression, co-immunoprecipitation, epigenetic profiling, ChIP-seq for JMJD5 as Sox2 target","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP showing Sox2-JMJD5 interaction, ChIP identifying JMJD5 as direct target, functional EC-specific conditional mouse model","pmids":["31232700"],"is_preprint":false},{"year":2022,"finding":"CRISPR-mediated SOX2 deletion in castration-resistant prostate cancer cells reveals that SOX2 promotes metabolic reprogramming including increased glycolysis, glycolytic capacity, basal/maximal oxidative respiration, and spare respiratory capacity. SOX2 ChIP-seq identified prostate-specific target genes (CERK, ECHS1, HS6SDT1, LPCAT4, PFKP, SLC16A3, SLC46A1, TST) distinct from canonical embryonic SOX2 targets.","method":"CRISPR KO, Seahorse metabolic assays, SOX2 ChIP-seq, metabolomics","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Moderate — CRISPR KO with multiple orthogonal metabolic readouts and genome-wide binding data, comprehensive single study","pmids":["35067686"],"is_preprint":false},{"year":2016,"finding":"In lung cancer cells, SOX2 bound the EPCAM promoter to induce EpCAM-p21Cip1-cyclin A2 signaling promoting cell proliferation, while SOX9 bound the SLUG promoter for invasion. Ectopic SOX2 expression inhibited SOX9 with increased H3K9me2 on the SOX9 promoter, establishing an epigenetic switch between SOX2 and SOX9 controlling cancer cell plasticity.","method":"ChIP, promoter binding assays, HDAC inhibition, ectopic expression, histone methylation analysis","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — ChIP at specific promoters plus functional and epigenetic assays, single lab","pmids":["27758880"],"is_preprint":false},{"year":2021,"finding":"DYRK1A promotes differentiation of glioblastoma stem cells by deactivating CDK5, which results in decreased SOX2 expression. The DYRK1A-CDK5-SOX2 pathway represents a regulatory axis controlling GSC stemness; DYRK1A inhibition insulates self-renewing GSCs from differentiation by maintaining CDK5 activity and SOX2 levels.","method":"DYRK1A inhibition/activation, CDK5 knockdown, SOX2 expression analysis, GSC differentiation assays","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — pathway epistasis established by sequential kinase inhibition with defined SOX2 expression readout, single lab","pmids":["33924599"],"is_preprint":false},{"year":2024,"finding":"PSMD7 (a deubiquitinating enzyme) deubiquitinates and stabilizes SOX2 protein in pancreatic cancer cells, increasing SOX2 protein levels and subsequently activating Notch1 signaling. Restoration of SOX2 expression abrogated the antitumor effect of PSMD7 knockdown.","method":"Co-immunoprecipitation, ubiquitination assays, PSMD7 knockdown, SOX2 rescue experiments, in vivo tumor assays","journal":"Cell & bioscience","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — co-IP plus ubiquitination assays and rescue experiments, single lab","pmids":["38494478"],"is_preprint":false},{"year":2011,"finding":"miR-126 inhibits SOX2 expression by targeting two binding sites in the 3'-UTR of SOX2 mRNA. Luciferase assays and gain/loss-of-function experiments confirmed this post-transcriptional repression. SOX2 overexpression was found to downregulate PLAC1, identifying PLAC1 as a downstream target of SOX2.","method":"Luciferase reporter assays (3'-UTR), miRNA gain/loss-of-function, siRNA knockdown, microarray after SOX2 overexpression","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — direct UTR binding demonstrated by reporter assay plus downstream target identification by microarray, single lab","pmids":["21304604"],"is_preprint":false},{"year":2016,"finding":"Sox2 interferes with Wnt signaling in tooth development by binding to β-catenin; Sox2 knockdown results in failure of cell migration from molar 1 to molar 2, and degradation of Wnt signaling caused by Sox2 knockdown results in lack of cell migration.","method":"Temporal Sox2 knockdown, DiI cell tracking assay, Wnt signaling analysis","journal":"Cell and tissue research","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — direct β-catenin binding (co-IP) plus functional migration tracking, single lab","pmids":["26846112"],"is_preprint":false},{"year":2019,"finding":"SOX2 expression in bladder cancer induces IGF2 expression (gene expression profiling), and SOX2-mediated spheroid formation under low-serum stress is inhibited by pharmacologic inhibition of AKT (MK2206) or IGF1R (linsitinib), placing IGF2-IGF1R-AKT downstream of SOX2.","method":"SOX2 overexpression/silencing, gene expression profiling, pharmacologic AKT and IGF1R inhibition, spheroid formation assays","journal":"Scientific reports","confidence":"Low","confidence_rationale":"Tier 3 / Weak — pathway placement by pharmacologic inhibition and expression profiling without direct binding or ChIP evidence for IGF2 as direct SOX2 target","pmids":["32427884"],"is_preprint":false},{"year":2017,"finding":"SOX2 targets acinar-specific genes and is essential for the survival of acinar but not ductal cells during salivary gland development. Genetic ablation of SOX2 results in failure to establish acini. Parasympathetic nerves regulate acinar cell generation via regulation of SOX2.","method":"Conditional SOX2 knockout, ChIP-seq for SOX2 target genes in salivary gland, genetic lineage tracing","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 / Moderate — conditional KO with specific acinar/ductal phenotype plus ChIP-seq for acinar targets and nerve-mediated regulation, single lab multiple methods","pmids":["28623666"],"is_preprint":false}],"current_model":"SOX2 is a pioneer transcription factor with an HMG DNA-binding domain that directly binds and distorts nucleosomal DNA to facilitate chromatin opening, and also binds RNA via a C-terminal motif to form ternary RNA/SOX2/DNA complexes; its transcriptional activity as an activator is context-dependent on partner factors (OCT4/KLF4 in pluripotency, p63 in squamous cancers), its protein stability is regulated by opposing ubiquitin ligase (CUL4A-DET1-COP1, UBE2S) and deubiquitylase (OTUD7B, PSMD7) activities, its nuclear localization and phosphorylation are controlled by CDK1 and AKT kinase signaling, and it executes tissue-specific roles in stem cell maintenance, lineage specification, and metabolic reprogramming by binding distinct genomic targets across different cell types."},"narrative":{"mechanistic_narrative":"SOX2 is an HMG-domain pioneer transcription factor that binds and locally distorts nucleosomal DNA to control chromatin accessibility, lineage specification, and stem-cell maintenance across diverse tissues [PMID:32350470, PMID:37691488]. Cryo-EM shows SOX2 engages nucleosomal DNA at superhelical location 2, detaches terminal DNA from the histone octamer, and repositions the histone H4 N-terminal tail to increase accessibility [PMID:32350470], and acute SOX2 depletion collapses thousands of accessible chromatin sites within an hour, with the subset it maintains being highly predictive of gene expression [PMID:37691488]. In pluripotency it cooperates with partner factors: OCT4-SOX2 differentially distort nucleosomal DNA depending on motif placement [PMID:32327602], SOX2 and KLF4 form a functional reprogramming core that co-binds the genome and remodels pluripotency enhancers [PMID:31722212], and during early embryogenesis SOX2 first occupies pre-accessible enhancers opened by other factors before redistributing to open or poise new enhancers [PMID:38096290]. SOX2 functions principally as a transcriptional activator, since substituting a VP16 activation domain enhances reprogramming while a repressor fusion abolishes it [PMID:28813671], and its intrinsically disordered C-terminal region rearranges upon DNA/nucleosome binding to expose two activation domains [PMID:38365983]. Beyond DNA, SOX2 binds double-stranded RNA via an HMG-box-associated RNA-binding motif, forming ternary RNA/SOX2/DNA complexes whose disruption impairs reprogramming [PMID:32286318, PMID:32016422]. SOX2 partner usage is context-dependent in cancer: it switches from OCT4 to p63 in squamous carcinomas to co-occupy loci and drive oncogenes such as ETV4 [PMID:24590290], partners with KLF5 to acquire new binding sites and activate endogenous retroviruses [PMID:33972779], and represses the Hippo activators NF2 and WWC1 to potentiate YAP [PMID:25832504, PMID:31560173]. It also reprograms metabolism, transactivating the SLC2A1/GLUT1 enhancer with p63 to fuel glucose influx and antioxidant capacity in squamous tumors [PMID:31412252] and driving prostate-specific metabolic target genes [PMID:35067686]. SOX2 protein stability is set by opposing ubiquitin enzymes—UBE2S-mediated K11 ubiquitination at K123 and the CUL4A-DET1-COP1 ligase promote degradation, while deubiquitylases OTUD7B and PSMD7 stabilize it [PMID:26292759, PMID:30405104, PMID:38494478]—and its nuclear localization and activity are controlled by CDK1 and AKT signaling [PMID:30297536, PMID:26498353]. Developmentally, SOX2 is required dosage-dependently for inner-ear neurogenesis [PMID:28642583], salivary acinar cell survival [PMID:28623666], and lens/nasal placode induction with Oct-1 [PMID:17140559], while acting as a context-dependent tumor suppressor that restrains Wnt-driven gastric adenoma [PMID:27498859].","teleology":[{"year":2006,"claim":"Established that SOX2 acts combinatorially with a POU partner to drive a defined developmental enhancer, framing its activity as context-dependent and partner-driven rather than autonomous.","evidence":"Genetic epistasis in double-mutant mice plus in vitro transactivation and transgenic enhancer assays at the Pax6 lens enhancer with Oct-1","pmids":["17140559"],"confidence":"High","gaps":["Did not resolve nucleosome-level binding mechanism","Limited to lens/nasal placode context"]},{"year":2014,"claim":"Showed SOX2 switches its transcription-factor partner in a tissue-specific manner, explaining how the same factor produces different transcriptional outputs in pluripotency versus cancer.","evidence":"ChIP-seq, co-IP and siRNA knockdown in squamous cell carcinoma defining SOX2-p63 co-occupancy and ETV4 dependence","pmids":["24590290"],"confidence":"High","gaps":["Did not define structural basis of partner selection","Generality across other SCC subtypes not fully mapped"]},{"year":2017,"claim":"Defined SOX2 as a transcriptional activator that establishes de novo enhancers during reprogramming, distinguishing activation from repression as the functionally relevant output.","evidence":"VP16/HP1 activation/repression domain swaps with reprogramming efficiency assays and ChIP-seq","pmids":["28813671"],"confidence":"High","gaps":["Mechanism of de novo enhancer selection not resolved","Did not address chromatin-opening kinetics"]},{"year":2020,"claim":"Resolved at near-atomic detail how SOX2 acts as a pioneer factor, showing it distorts nucleosomal DNA and detaches terminal DNA to increase accessibility, alone and with OCT4.","evidence":"Cryo-EM structures of SOX2 and OCT4-SOX2 bound to nucleosomes","pmids":["32350470","32327602"],"confidence":"High","gaps":["Static structures do not capture chromatin-opening dynamics in cells","Role of partner stoichiometry in vivo unaddressed"]},{"year":2020,"claim":"Revealed an unexpected RNA-binding function, defining a C-terminal RNA-binding motif that forms ternary RNA/SOX2/DNA complexes and contributes to reprogramming.","evidence":"In vitro binding, CLIP and fRIP-seq in ES cells, plus RBM deletion and reprogramming assays","pmids":["32286318","32016422"],"confidence":"High","gaps":["Functional consequence of most SOX2-RNA interactions unknown","Whether RNA binding tunes DNA binding in vivo unresolved"]},{"year":2020,"claim":"Connected SOX2 to R-loop biology, showing it inhibits Ddx5 resolvase activity to facilitate reprogramming, linking its nucleic-acid binding to chromatin/genome maintenance.","evidence":"Co-IP, R-loop profiling and reprogramming assays with RNaseH1 perturbation","pmids":["32704541"],"confidence":"Medium","gaps":["Single-lab co-IP for Sox2-Ddx5 interaction","Direct effect on R-loop structures at SOX2 targets not mapped"]},{"year":2023,"claim":"Distinguished functional from incidental SOX2 binding by showing acute depletion rapidly collapses a subset of accessible sites that predict gene expression, defining the productive pioneer activity.","evidence":"Acute protein depletion with ATAC-seq, nascent transcription and CRISPR validation","pmids":["37691488"],"confidence":"High","gaps":["What distinguishes productive from dispensable sites mechanistically","Generalizability beyond ES cells"]},{"year":2023,"claim":"Mapped SOX2 enhancer logic in vivo and at its own locus, showing it occupies pre-accessible enhancers before redistributing, and that distal autonomous and context-dependent DHSs control its own expression.","evidence":"In vivo embryo ChIP-seq/ATAC-seq across stages and endogenous locus engineering (Big-IN) of the Sox2 enhancer cluster","pmids":["38096290","36931273"],"confidence":"High","gaps":["Factors directing SOX2 redistribution not fully identified","Enhancer rules may differ in non-embryonic tissues"]},{"year":2024,"claim":"Provided the biophysical basis for SOX2 activation, showing DNA/nucleosome binding rearranges the disordered C-terminal region to expose activation domains.","evidence":"Single-molecule FRET, NMR and molecular simulations","pmids":["38365983"],"confidence":"High","gaps":["Whether IDR rearrangement recruits specific coactivators unproven","In-cell relevance of conformational ensemble not tested"]},{"year":2024,"claim":"Consolidated SOX2 as a substrate of opposing ubiquitin/deubiquitin enzymes, establishing post-translational stability control as a major regulatory layer governing its levels in development and cancer.","evidence":"Ubiquitination/deubiquitination assays, site-directed mutagenesis (K123), and rescue experiments across ES, NPC and cancer systems (UBE2S, CUL4A-DET1-COP1, OTUD7B, PSMD7)","pmids":["26292759","30405104","38494478"],"confidence":"High","gaps":["Upstream signals selecting ligase vs deubiquitylase context unknown","Crosstalk with CDK1/AKT phosphorylation not integrated"]},{"year":2024,"claim":"Defined tissue-specific transcriptional programs and partner-dependent oncogenic functions, from metabolic reprogramming to Hippo/Wnt modulation and squamous ERV activation.","evidence":"ChIP-seq, CRISPR KO, metabolic assays and organoid/tumor models across squamous, prostate, gastric and esophageal contexts (p63, KLF5, NF2/WWC1, SLC2A1)","pmids":["31412252","35067686","27498859","33972779","25832504"],"confidence":"High","gaps":["How identical HMG domain achieves divergent tissue target selection unresolved","Direct vs indirect status of some metabolic targets not all ChIP-validated"]},{"year":null,"claim":"It remains unknown how SOX2 integrates its DNA, RNA, partner-factor, conformational, and post-translational regulatory inputs into a single predictive model of context-specific target selection.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying framework linking partner identity to genomic redistribution","Crosstalk between RNA binding, IDR dynamics and chromatin opening unmapped","Signaling-to-stability-to-localization axis not reconstituted"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,1,22]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[12,5,14]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[2,3]},{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[0]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[6,9]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[0,22]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[9]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[12,5,14]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[0,22,20]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[10,26,38]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[5,18,31]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[7,8,34]}],"complexes":[],"partners":["POU5F1","KLF4","TP63","KLF5","POU2F1","DDX5","COP1","OTUD7B"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P48431","full_name":"Transcription factor SOX-2","aliases":[],"length_aa":317,"mass_kda":34.3,"function":"Transcription factor that forms a trimeric complex with OCT4 on DNA and controls the expression of a number of genes involved in embryonic development such as YES1, FGF4, UTF1 and ZFP206 (By similarity). Binds to the proximal enhancer region of NANOG (By similarity). Critical for early embryogenesis and for embryonic stem cell pluripotency (PubMed:18035408). Downstream SRRT target that mediates the promotion of neural stem cell self-renewal (By similarity). Keeps neural cells undifferentiated by counteracting the activity of proneural proteins and suppresses neuronal differentiation (By similarity). May function as a switch in neuronal development (By similarity)","subcellular_location":"Nucleus speckle; Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/P48431/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SOX2","classification":"Not Classified","n_dependent_lines":86,"n_total_lines":1208,"dependency_fraction":0.07119205298013245},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SOX2","total_profiled":1310},"omim":[{"mim_id":"621222","title":"LINE1-TYPE TRANSPOSASE DOMAIN-CONTAINING PROTEIN 1; L1TD1","url":"https://www.omim.org/entry/621222"},{"mim_id":"620940","title":"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblL TYPE; MAHCL","url":"https://www.omim.org/entry/620940"},{"mim_id":"620637","title":"CADHERIN-LIKE DOMAIN- AND PC-ESTERASE DOMAIN-CONTAINING PROTEIN 1; CPED1","url":"https://www.omim.org/entry/620637"},{"mim_id":"620050","title":"PHD FINGER PROTEIN 20-LIKE 1; PHF20L1","url":"https://www.omim.org/entry/620050"},{"mim_id":"619623","title":"LEUCINE-RICH REPEAT NEURONAL PROTEIN 1; LRRN1","url":"https://www.omim.org/entry/619623"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":71.9},{"tissue":"esophagus","ntpm":22.9}],"url":"https://www.proteinatlas.org/search/SOX2"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P48431","domains":[{"cath_id":"1.10.30.10","chopping":"44-106","consensus_level":"medium","plddt":96.8829,"start":44,"end":106}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P48431","model_url":"https://alphafold.ebi.ac.uk/files/AF-P48431-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P48431-F1-predicted_aligned_error_v6.png","plddt_mean":59.84},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SOX2","jax_strain_url":"https://www.jax.org/strain/search?query=SOX2"},"sequence":{"accession":"P48431","fasta_url":"https://rest.uniprot.org/uniprotkb/P48431.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P48431/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P48431"}},"corpus_meta":[{"pmid":"31412296","id":"PMC_31412296","title":"SOX2 in development and cancer biology.","date":"2019","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/31412296","citation_count":287,"is_preprint":false},{"pmid":"19733254","id":"PMC_19733254","title":"Sox2 roles in neural stem cells.","date":"2009","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/19733254","citation_count":278,"is_preprint":false},{"pmid":"25114775","id":"PMC_25114775","title":"SOX2 and cancer: current research and its implications in the clinic.","date":"2014","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25114775","citation_count":220,"is_preprint":false},{"pmid":"23416461","id":"PMC_23416461","title":"The multiple roles for Sox2 in stem cell maintenance and tumorigenesis.","date":"2013","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/23416461","citation_count":217,"is_preprint":false},{"pmid":"32350470","id":"PMC_32350470","title":"Nucleosome-bound SOX2 and SOX11 structures elucidate pioneer factor function.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32350470","citation_count":206,"is_preprint":false},{"pmid":"25832504","id":"PMC_25832504","title":"Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25832504","citation_count":206,"is_preprint":false},{"pmid":"32327602","id":"PMC_32327602","title":"Mechanisms of OCT4-SOX2 motif readout on nucleosomes.","date":"2020","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/32327602","citation_count":187,"is_preprint":false},{"pmid":"15812812","id":"PMC_15812812","title":"SOX2 anophthalmia syndrome.","date":"2005","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/15812812","citation_count":184,"is_preprint":false},{"pmid":"28388544","id":"PMC_28388544","title":"The dark side of SOX2: cancer - a comprehensive overview.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28388544","citation_count":178,"is_preprint":false},{"pmid":"32728033","id":"PMC_32728033","title":"Functional characterization of SOX2 as an anticancer target.","date":"2020","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32728033","citation_count":176,"is_preprint":false},{"pmid":"31477842","id":"PMC_31477842","title":"SOX2 protein biochemistry in stemness, reprogramming, and cancer: the PI3K/AKT/SOX2 axis and beyond.","date":"2019","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/31477842","citation_count":151,"is_preprint":false},{"pmid":"24590290","id":"PMC_24590290","title":"SOX2 and p63 colocalize at genetic loci in squamous cell carcinomas.","date":"2014","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/24590290","citation_count":148,"is_preprint":false},{"pmid":"21304604","id":"PMC_21304604","title":"MicroRNA-126 inhibits SOX2 expression and contributes to gastric carcinogenesis.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21304604","citation_count":148,"is_preprint":false},{"pmid":"21518820","id":"PMC_21518820","title":"SOX2 expression and amplification in gliomas and glioma cell lines.","date":"2011","source":"Cancer genomics & proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/21518820","citation_count":143,"is_preprint":false},{"pmid":"17604700","id":"PMC_17604700","title":"Expression of LHX3 and SOX2 during mouse inner ear development.","date":"2007","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/17604700","citation_count":133,"is_preprint":false},{"pmid":"27225481","id":"PMC_27225481","title":"Yin Yang 1 is associated with cancer stem cell transcription factors (SOX2, OCT4, BMI1) and clinical implication.","date":"2016","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/27225481","citation_count":123,"is_preprint":false},{"pmid":"30297536","id":"PMC_30297536","title":"CDK1 Interacts with Sox2 and Promotes Tumor Initiation in Human Melanoma.","date":"2018","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30297536","citation_count":105,"is_preprint":false},{"pmid":"20852734","id":"PMC_20852734","title":"Expression of pax6 and sox2 in adult olfactory epithelium.","date":"2010","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/20852734","citation_count":104,"is_preprint":false},{"pmid":"20855650","id":"PMC_20855650","title":"Sox2 activates cell proliferation and differentiation in the respiratory epithelium.","date":"2010","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/20855650","citation_count":102,"is_preprint":false},{"pmid":"17140559","id":"PMC_17140559","title":"Sox2 and Pou2f1 interact to control lens and olfactory placode development.","date":"2006","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/17140559","citation_count":94,"is_preprint":false},{"pmid":"22184093","id":"PMC_22184093","title":"SOX2 contributes to melanoma cell invasion.","date":"2011","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/22184093","citation_count":92,"is_preprint":false},{"pmid":"25456004","id":"PMC_25456004","title":"Sox2 expression involvement in the oncogenicity and radiochemoresistance of oral cancer stem cells.","date":"2014","source":"Oral oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25456004","citation_count":90,"is_preprint":false},{"pmid":"32286318","id":"PMC_32286318","title":"The Sox2 transcription factor binds RNA.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32286318","citation_count":87,"is_preprint":false},{"pmid":"28623666","id":"PMC_28623666","title":"SOX2 regulates acinar cell development in the salivary gland.","date":"2017","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/28623666","citation_count":81,"is_preprint":false},{"pmid":"33972779","id":"PMC_33972779","title":"Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence.","date":"2021","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33972779","citation_count":80,"is_preprint":false},{"pmid":"25781683","id":"PMC_25781683","title":"Overview of the roles of Sox2 in stem cell and development.","date":"2015","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25781683","citation_count":78,"is_preprint":false},{"pmid":"30694767","id":"PMC_30694767","title":"miR-145-5p Suppresses Breast Cancer Progression by Inhibiting SOX2.","date":"2018","source":"The Journal of surgical research","url":"https://pubmed.ncbi.nlm.nih.gov/30694767","citation_count":72,"is_preprint":false},{"pmid":"18162777","id":"PMC_18162777","title":"Sox2 expression in brain tumors: a reflection of the neuroglial differentiation pathway.","date":"2008","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/18162777","citation_count":70,"is_preprint":false},{"pmid":"31412252","id":"PMC_31412252","title":"p63 and SOX2 Dictate Glucose Reliance and Metabolic Vulnerabilities in Squamous Cell Carcinomas.","date":"2019","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/31412252","citation_count":69,"is_preprint":false},{"pmid":"30366514","id":"PMC_30366514","title":"Targeting SOX2 in anticancer therapy.","date":"2018","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/30366514","citation_count":67,"is_preprint":false},{"pmid":"35067686","id":"PMC_35067686","title":"SOX2 mediates metabolic reprogramming of prostate cancer cells.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/35067686","citation_count":65,"is_preprint":false},{"pmid":"29553487","id":"PMC_29553487","title":"Sox2 haploinsufficiency primes regeneration and Wnt responsiveness in the mouse cochlea.","date":"2018","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/29553487","citation_count":62,"is_preprint":false},{"pmid":"31556488","id":"PMC_31556488","title":"Endogenous fluctuations of OCT4 and SOX2 bias pluripotent cell fate decisions.","date":"2019","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/31556488","citation_count":61,"is_preprint":false},{"pmid":"27498859","id":"PMC_27498859","title":"Sox2 Suppresses Gastric Tumorigenesis in Mice.","date":"2016","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/27498859","citation_count":61,"is_preprint":false},{"pmid":"30405104","id":"PMC_30405104","title":"Dynamic ubiquitylation of Sox2 regulates proteostasis and governs neural progenitor cell differentiation.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30405104","citation_count":60,"is_preprint":false},{"pmid":"19369635","id":"PMC_19369635","title":"Differential expression of SOX2 and SOX17 in testicular germ cell tumors.","date":"2009","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/19369635","citation_count":57,"is_preprint":false},{"pmid":"27758880","id":"PMC_27758880","title":"Epigenetic Switch between SOX2 and SOX9 Regulates Cancer Cell Plasticity.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27758880","citation_count":56,"is_preprint":false},{"pmid":"32704541","id":"PMC_32704541","title":"R-loops coordinate with SOX2 in regulating reprogramming to pluripotency.","date":"2020","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/32704541","citation_count":53,"is_preprint":false},{"pmid":"36931273","id":"PMC_36931273","title":"Synthetic regulatory genomics uncovers enhancer context dependence at the Sox2 locus.","date":"2023","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/36931273","citation_count":52,"is_preprint":false},{"pmid":"21410764","id":"PMC_21410764","title":"SOX2 and nestin expression in human melanoma: an immunohistochemical and experimental study.","date":"2011","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/21410764","citation_count":51,"is_preprint":false},{"pmid":"26292759","id":"PMC_26292759","title":"Ube2s regulates Sox2 stability and mouse ES cell maintenance.","date":"2015","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/26292759","citation_count":48,"is_preprint":false},{"pmid":"30907312","id":"PMC_30907312","title":"Sox2: A Regulatory Factor in Tumorigenesis and Metastasis.","date":"2019","source":"Current protein & peptide science","url":"https://pubmed.ncbi.nlm.nih.gov/30907312","citation_count":46,"is_preprint":false},{"pmid":"25057212","id":"PMC_25057212","title":"Sox2 regulates cholinergic amacrine cell positioning and dendritic stratification in the retina.","date":"2014","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25057212","citation_count":43,"is_preprint":false},{"pmid":"32016422","id":"PMC_32016422","title":"Concurrent binding to DNA and RNA facilitates the pluripotency reprogramming activity of Sox2.","date":"2020","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/32016422","citation_count":42,"is_preprint":false},{"pmid":"32492707","id":"PMC_32492707","title":"TRIM24 promotes stemness and invasiveness of glioblastoma cells via activating Sox2 expression.","date":"2020","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32492707","citation_count":41,"is_preprint":false},{"pmid":"28642583","id":"PMC_28642583","title":"SOX2 is required for inner ear neurogenesis.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28642583","citation_count":41,"is_preprint":false},{"pmid":"27186426","id":"PMC_27186426","title":"Paradoxical role of SOX2 in gastric cancer.","date":"2016","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27186426","citation_count":40,"is_preprint":false},{"pmid":"31610800","id":"PMC_31610800","title":"Sox2 promotes expression of the ST6Gal-I glycosyltransferase in ovarian cancer cells.","date":"2019","source":"Journal of ovarian research","url":"https://pubmed.ncbi.nlm.nih.gov/31610800","citation_count":39,"is_preprint":false},{"pmid":"35626641","id":"PMC_35626641","title":"Deconstructing Sox2 Function in Brain Development and Disease.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/35626641","citation_count":38,"is_preprint":false},{"pmid":"26498353","id":"PMC_26498353","title":"Molecular and functional interactions between AKT and SOX2 in breast carcinoma.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26498353","citation_count":38,"is_preprint":false},{"pmid":"31583686","id":"PMC_31583686","title":"Unique and redundant roles of SOX2 and SOX17 in regulating the germ cell tumor fate.","date":"2019","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31583686","citation_count":38,"is_preprint":false},{"pmid":"27230973","id":"PMC_27230973","title":"Sox2: regulation of expression and contribution to brain tumors.","date":"2016","source":"CNS oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27230973","citation_count":36,"is_preprint":false},{"pmid":"38096290","id":"PMC_38096290","title":"Multifaceted SOX2-chromatin interaction underpins pluripotency progression in early embryos.","date":"2023","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/38096290","citation_count":35,"is_preprint":false},{"pmid":"32029747","id":"PMC_32029747","title":"Sox2 controls Schwann cell self-organization through fibronectin fibrillogenesis.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32029747","citation_count":35,"is_preprint":false},{"pmid":"23154195","id":"PMC_23154195","title":"Sox2 regulation of hair cell development: incoherence makes sense.","date":"2012","source":"Hearing research","url":"https://pubmed.ncbi.nlm.nih.gov/23154195","citation_count":35,"is_preprint":false},{"pmid":"31232700","id":"PMC_31232700","title":"Elevated endothelial Sox2 causes lumen disruption and cerebral arteriovenous malformations.","date":"2019","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/31232700","citation_count":35,"is_preprint":false},{"pmid":"31640140","id":"PMC_31640140","title":"SOX2 Expression Is an Independent Predictor of Oral Cancer Progression.","date":"2019","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31640140","citation_count":35,"is_preprint":false},{"pmid":"18836133","id":"PMC_18836133","title":"Hypermethylation of SOX2 gene in hydatidiform mole and choriocarcinoma.","date":"2008","source":"Reproductive sciences (Thousand Oaks, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/18836133","citation_count":33,"is_preprint":false},{"pmid":"28813671","id":"PMC_28813671","title":"OCT4 and SOX2 Work as Transcriptional Activators in Reprogramming Human Fibroblasts.","date":"2017","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/28813671","citation_count":33,"is_preprint":false},{"pmid":"24201161","id":"PMC_24201161","title":"Clinicopathologic implications of EpCAM and Sox2 expression in breast cancer.","date":"2013","source":"Clinical breast cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24201161","citation_count":32,"is_preprint":false},{"pmid":"17464316","id":"PMC_17464316","title":"Expression of Sox2 in mature and immature teratomas of central nervous system.","date":"2007","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/17464316","citation_count":32,"is_preprint":false},{"pmid":"25339068","id":"PMC_25339068","title":"Slug promotes hepatocellular cancer cell progression by increasing sox2 and nanog expression.","date":"2014","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/25339068","citation_count":32,"is_preprint":false},{"pmid":"31722212","id":"PMC_31722212","title":"Sox2 and Klf4 as the Functional Core in Pluripotency Induction without Exogenous Oct4.","date":"2019","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/31722212","citation_count":32,"is_preprint":false},{"pmid":"36738502","id":"PMC_36738502","title":"SOX2-associated signaling pathways regulate biological phenotypes of cancers.","date":"2023","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/36738502","citation_count":31,"is_preprint":false},{"pmid":"18379823","id":"PMC_18379823","title":"Expression of Sox2 in mouse taste buds and its relation to innervation.","date":"2008","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/18379823","citation_count":31,"is_preprint":false},{"pmid":"26960758","id":"PMC_26960758","title":"SOX2 inhibits metastasis in gastric cancer.","date":"2016","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26960758","citation_count":29,"is_preprint":false},{"pmid":"38494478","id":"PMC_38494478","title":"Deubiquitinase PSMD7 facilitates pancreatic cancer progression through activating Nocth1 pathway via modifying SOX2 degradation.","date":"2024","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/38494478","citation_count":28,"is_preprint":false},{"pmid":"22576801","id":"PMC_22576801","title":"Oct4 and Sox2 are overexpressed in human neuroblastoma and inhibited by chemotherapy.","date":"2012","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/22576801","citation_count":28,"is_preprint":false},{"pmid":"28368416","id":"PMC_28368416","title":"Sox2 is dispensable for primary melanoma and metastasis formation.","date":"2017","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/28368416","citation_count":28,"is_preprint":false},{"pmid":"32905832","id":"PMC_32905832","title":"SOX2 and squamous cancers.","date":"2020","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/32905832","citation_count":27,"is_preprint":false},{"pmid":"24482053","id":"PMC_24482053","title":"Clinicopathologic significance of Sox2, CD44 and CD44v6 expression in intrahepatic cholangiocarcinoma.","date":"2014","source":"Pathology oncology research : POR","url":"https://pubmed.ncbi.nlm.nih.gov/24482053","citation_count":27,"is_preprint":false},{"pmid":"29574045","id":"PMC_29574045","title":"SOX2 expression diminishes with ageing in several tissues in mice and humans.","date":"2018","source":"Mechanisms of ageing and development","url":"https://pubmed.ncbi.nlm.nih.gov/29574045","citation_count":26,"is_preprint":false},{"pmid":"34286693","id":"PMC_34286693","title":"SOX21 modulates SOX2-initiated differentiation of epithelial cells in the extrapulmonary airways.","date":"2021","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/34286693","citation_count":26,"is_preprint":false},{"pmid":"34583803","id":"PMC_34583803","title":"MicroRNAs regulating SOX2 in cancer progression and therapy response.","date":"2021","source":"Expert reviews in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34583803","citation_count":24,"is_preprint":false},{"pmid":"36717549","id":"PMC_36717549","title":"Reciprocal regulation of LINC00941 and SOX2 promotes progression of esophageal squamous cell carcinoma.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36717549","citation_count":24,"is_preprint":false},{"pmid":"38365983","id":"PMC_38365983","title":"DNA binding redistributes activation domain ensemble and accessibility in pioneer factor Sox2.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38365983","citation_count":24,"is_preprint":false},{"pmid":"32427884","id":"PMC_32427884","title":"Critical role of SOX2-IGF2 signaling in aggressiveness of bladder cancer.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32427884","citation_count":24,"is_preprint":false},{"pmid":"37691488","id":"PMC_37691488","title":"Pioneer activity distinguishes activating from non-activating SOX2 binding sites.","date":"2023","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/37691488","citation_count":24,"is_preprint":false},{"pmid":"37063420","id":"PMC_37063420","title":"LncRNA GSCAR promotes glioma stem cell maintenance via stabilizing SOX2 expression.","date":"2023","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37063420","citation_count":23,"is_preprint":false},{"pmid":"35861233","id":"PMC_35861233","title":"SOX2 transcription factor binding and function.","date":"2022","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/35861233","citation_count":23,"is_preprint":false},{"pmid":"29178409","id":"PMC_29178409","title":"Sox2 regulates astrocytic and vascular development in the retina.","date":"2017","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/29178409","citation_count":23,"is_preprint":false},{"pmid":"31344986","id":"PMC_31344986","title":"Sox2 dosage: A critical determinant in the functions of Sox2 in both normal and tumor cells.","date":"2019","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31344986","citation_count":22,"is_preprint":false},{"pmid":"30510261","id":"PMC_30510261","title":"Crosstalk between SOX2 and cytokine signaling in endometrial carcinoma.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30510261","citation_count":22,"is_preprint":false},{"pmid":"31693489","id":"PMC_31693489","title":"circ_0005273 promotes thyroid carcinoma progression by SOX2 expression.","date":"2020","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31693489","citation_count":22,"is_preprint":false},{"pmid":"30723235","id":"PMC_30723235","title":"SIX1 represses senescence and promotes SOX2-mediated cellular plasticity during tumorigenesis.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30723235","citation_count":21,"is_preprint":false},{"pmid":"35930824","id":"PMC_35930824","title":"SOX2 and PRAME in the \"reprogramming\" of seminoma cells.","date":"2022","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/35930824","citation_count":20,"is_preprint":false},{"pmid":"33924599","id":"PMC_33924599","title":"DYRK1A Negatively Regulates CDK5-SOX2 Pathway and Self-Renewal of Glioblastoma Stem Cells.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33924599","citation_count":20,"is_preprint":false},{"pmid":"24659665","id":"PMC_24659665","title":"Expression of Sox2 in cervical squamous cell carcinoma.","date":"2014","source":"Journal of B.U.ON. : official journal of the Balkan Union of Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24659665","citation_count":20,"is_preprint":false},{"pmid":"24656096","id":"PMC_24656096","title":"SOX2 expression in hypopharyngeal, laryngeal, and sinonasal squamous cell carcinoma.","date":"2013","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24656096","citation_count":20,"is_preprint":false},{"pmid":"30635613","id":"PMC_30635613","title":"SOX2 participates in spermatogenesis of Zhikong scallop Chlamys farreri.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30635613","citation_count":20,"is_preprint":false},{"pmid":"35858560","id":"PMC_35858560","title":"Sox2 in the dermal papilla regulates hair follicle pigmentation.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/35858560","citation_count":19,"is_preprint":false},{"pmid":"31560173","id":"PMC_31560173","title":"SOX2 antagonizes WWC1 to drive YAP1 activation in esophageal squamous cell carcinoma.","date":"2019","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31560173","citation_count":18,"is_preprint":false},{"pmid":"25263324","id":"PMC_25263324","title":"Neuronal expression of SOX2 is enriched in specific hypothalamic cell groups.","date":"2014","source":"Journal of chemical neuroanatomy","url":"https://pubmed.ncbi.nlm.nih.gov/25263324","citation_count":18,"is_preprint":false},{"pmid":"26846112","id":"PMC_26846112","title":"Sox2 contributes to tooth development via Wnt signaling.","date":"2016","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/26846112","citation_count":18,"is_preprint":false},{"pmid":"27592260","id":"PMC_27592260","title":"Sox2: To crest or not to crest?","date":"2016","source":"Seminars in cell & developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/27592260","citation_count":17,"is_preprint":false},{"pmid":"37120706","id":"PMC_37120706","title":"Capsaicin Reduces Cancer Stemness and Inhibits Metastasis by Downregulating SOX2 and EZH2 in Osteosarcoma.","date":"2023","source":"The American journal of Chinese medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37120706","citation_count":17,"is_preprint":false},{"pmid":"31718604","id":"PMC_31718604","title":"Glioma SOX2 expression decreased after adjuvant therapy.","date":"2019","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31718604","citation_count":17,"is_preprint":false},{"pmid":"30403311","id":"PMC_30403311","title":"Regulation of glioma cell invasion by 3q26 gene products PIK3CA, SOX2 and OPA1.","date":"2018","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/30403311","citation_count":16,"is_preprint":false},{"pmid":"35733702","id":"PMC_35733702","title":"OCT4, SOX2 and NANOG co-regulate glycolysis and participate in somatic induced reprogramming.","date":"2022","source":"Cytotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/35733702","citation_count":15,"is_preprint":false},{"pmid":"36794954","id":"PMC_36794954","title":"High Sox2 expression predicts taste lineage competency of lingual progenitors in vitro.","date":"2023","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/36794954","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":44514,"output_tokens":9107,"usd":0.135074,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19428,"output_tokens":4330,"usd":0.102695,"stage2_stop_reason":"end_turn"},"total_usd":0.237769,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2020,\n      \"finding\": \"Cryo-EM structures of SOX2 HMG domain bound to nucleosomes show that SOX2 binds and locally distorts nucleosomal DNA at superhelical location 2, facilitates detachment of terminal nucleosomal DNA from the histone octamer to increase DNA accessibility, and repositions the N-terminal tail of histone H4 (including K16), suggesting incompatibility with higher-order nucleosome stacking.\",\n      \"method\": \"Cryo-electron microscopy structure determination\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — cryo-EM structures with functional validation of pioneer factor mechanism, published in high-impact journal with multiple structural observations\",\n      \"pmids\": [\"32350470\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Cryo-EM structures of OCT4-SOX2 bound to nucleosomes at two preferred positions show that OCT4-SOX2 differentially distort nucleosomal DNA depending on motif location; at one position, OCT4-SOX2 removes DNA from histone H2A and H3, while at an inverted motif only local DNA distortions are induced. OCT4 uses one of its two DNA-binding domains to engage DNA in both structures.\",\n      \"method\": \"Cryo-electron microscopy structure determination with base-pair resolution in vitro TF engagement mapping\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — cryo-EM structures at two positions with base-pair resolution binding data, multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"32327602\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SOX2 directly binds RNA through its HMG DNA-binding domain in vitro with high affinity, primarily interacting with double-stranded RNA in a non-sequence-specific fashion. In mouse embryonic stem cells, UV-crosslinked immunoprecipitation (CLIP) confirmed direct SOX2-RNA binding in vivo, identifying over a thousand SOX2-RNA interactions by fRIP-seq.\",\n      \"method\": \"In vitro binding assays, UV-crosslinked immunoprecipitation (CLIP), fRIP-seq\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct in vitro binding with domain mapping plus orthogonal in vivo CLIP, multiple methods in one study\",\n      \"pmids\": [\"32286318\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SOX2 binds RNA via a 60-amino-acid RNA-binding motif (RBM) positioned C-terminally of the HMG box, forming ternary RNA/SOX2/DNA complexes. Deletion of the RBM does not affect target gene selection but reduces binding to pluripotency-related transcripts, alters exon usage, and impairs reprogramming of somatic cells to pluripotency.\",\n      \"method\": \"In vitro binding assays, domain deletion mutagenesis, reprogramming efficiency assays, RNA binding assays in mouse and human cells\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — domain mutagenesis combined with functional reprogramming assays and binding experiments, multiple orthogonal methods\",\n      \"pmids\": [\"32016422\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"SOX2 antagonizes the Hippo pathway to maintain cancer stem cells in osteosarcomas by directly repressing two Hippo activators, NF2 (Merlin) and WWC1 (Kibra), leading to exaggerated YAP function. This SOX2-Hippo axis is conserved in glioblastomas.\",\n      \"method\": \"ChIP, luciferase reporter assays, siRNA knockdown, tumor growth assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct promoter binding by ChIP combined with functional knockdown and rescue experiments, replicated across cancer types\",\n      \"pmids\": [\"25832504\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"In squamous cell carcinomas (SCCs), SOX2 preferentially interacts with the transcription factor p63 (rather than OCT4 as in ES cells), and SOX2-p63 co-occupy a large number of genomic loci. SOX2 and p63 jointly regulate gene expression including the oncogene ETV4, which is essential for SOX2-amplified SCC cell survival.\",\n      \"method\": \"ChIP-seq, co-immunoprecipitation, gene expression analysis, siRNA knockdown\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide ChIP-seq plus functional validation, demonstrates context-dependent partner switching from OCT4 to p63\",\n      \"pmids\": [\"24590290\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CDK1 physically interacts with SOX2 and promotes its nuclear localization, phosphorylation, and transcriptional activity. Blockade or knockdown of CDK1 reduces phosphorylation, nuclear localization, and transcriptional activity of SOX2, and CDK1-driven tumor-initiating capacity is substantially reduced by SOX2 knockout.\",\n      \"method\": \"Proteomic co-immunoprecipitation, pharmacologic CDK1 inhibition, CRISPR knockout, spheroid and xenograft assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP plus multiple functional assays including KO rescue, single lab but orthogonal methods\",\n      \"pmids\": [\"30297536\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The ubiquitin-conjugating enzyme UBE2S mediates K11-linked polyubiquitin chain formation at SOX2-K123, marking SOX2 for proteasomal degradation. UBE2S fine-tunes SOX2 protein levels and reinforces ES cell self-renewal while repressing SOX2-mediated neural ectodermal differentiation.\",\n      \"method\": \"Ubiquitination assays, site-directed mutagenesis (K123 residue), proteasome inhibition, ES cell differentiation assays\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — identified specific ubiquitination site by mutagenesis plus functional consequences in ES cells, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"26292759\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The E3 ubiquitin ligase complex CUL4A-DET1-COP1 ubiquitylates SOX2 (with COP1 as the substrate receptor interacting directly with SOX2) to promote its degradation, while the deubiquitylase OTUD7B removes polyubiquitin chains from SOX2 to stabilize it. These opposing enzymes govern SOX2 protein stability during neural progenitor cell differentiation.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, siRNA knockdown, western blot during NPC differentiation\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding shown by co-IP plus opposing functional knockdowns with differentiation phenotype, multiple orthogonal methods in single lab\",\n      \"pmids\": [\"30405104\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"AKT physically interacts with SOX2 protein and modulates its subcellular distribution. AKT kinase inhibition results in enhanced cytoplasmic retention of SOX2 (presumably via impaired nuclear import) and successive cytoplasmic proteasomal degradation. Ectopic SOX2 expression restores clonogenicity and tumorigenicity of AKT-inhibited cells.\",\n      \"method\": \"Co-immunoprecipitation, subcellular fractionation, pharmacologic AKT inhibition, rescue overexpression experiments, xenograft assays\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus localization and functional rescue, single lab with orthogonal methods\",\n      \"pmids\": [\"26498353\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"SOX2 forms a complex with Oct-1 (encoded by Pou2f1) at specific DNA-binding sites to cooperatively transactivate the Pax6 lens ectoderm enhancer. Genetic combination of Sox2 and Pou2f1 mutant alleles causes impaired lens placode induction and complete failure of nasal placode induction in mice.\",\n      \"method\": \"Genetic epistasis (double mutant mice), in vitro transactivation assays, transgenic mouse enhancer assays\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis in mice combined with in vitro transactivation and transgenic enhancer validation, multiple orthogonal methods\",\n      \"pmids\": [\"17140559\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Sox2 interacts with the reprogramming barrier factor Ddx5 and inhibits the resolvase activity of Ddx5 on R-loops, thereby facilitating somatic cell reprogramming. Sox2, but not other Yamanaka factors, overcomes the inhibitory effects of RNaseH1 activity loss on reprogramming.\",\n      \"method\": \"Co-immunoprecipitation, R-loop profiling, reprogramming efficiency assays with RNaseH1 depletion/inactivation\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus functional reprogramming assays, single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"32704541\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"SOX2 acts as a transcriptional activator during reprogramming: substituting SOX2-VP16 for wild-type SOX2 increased reprogramming efficiency and rate, whereas SOX2-HP1 (a repressor fusion) eliminated reprogramming. At early reprogramming stages, DNA-bound SOX2 was embedded in putative enhancers, about half of which were created de novo.\",\n      \"method\": \"Domain swap (VP16/HP1 fusions), reprogramming efficiency assays, ChIP-seq\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — activation domain substitution mutagenesis with functional reprogramming outcome plus ChIP-seq, clear mechanistic conclusion\",\n      \"pmids\": [\"28813671\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SOX2 directly represses NF2 and WWC1 in esophageal squamous cell carcinoma, activating YAP1. Multiple SOX2 binding peaks at the WWC1 locus and inverse correlation between SOX2 and WWC1 expression were found, and SOX2 gain-of-function promoted nuclear YAP1 expression while SOX2 silencing inhibited YAP1 activation.\",\n      \"method\": \"ChIP-seq, gene expression analysis, SOX2 overexpression/knockdown, YAP1 localization assays\",\n      \"journal\": \"Cancer medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq binding plus gain/loss-of-function functional experiments, single lab\",\n      \"pmids\": [\"31560173\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Sox2 loss in gastric epithelial cells enhances tumor formation in Apc-deficient gastric cells by inducing Tcf/Lef-dependent transcription and upregulating intestinal metaplasia-associated genes, identifying Sox2 as a context-dependent tumor suppressor in the stomach that restrains Wnt-driven adenoma formation.\",\n      \"method\": \"ChIP-seq, conditional Sox2 knockout mice, Apc/Wnt-driven tumor model, luciferase reporter assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO in vivo tumor model plus ChIP-seq and reporter assays, mechanistic pathway placement via Wnt/Tcf/Lef\",\n      \"pmids\": [\"27498859\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"SOX2 knockdown in melanoma cells with high constitutive SOX2 expression resulted in 4.5-fold decreased invasiveness in vitro, associated with 87.8% reduction in MMP-3 mRNA. Conversely, SOX2 overexpression increased invasiveness 3.8-fold. MMP-3 knockdown inhibited invasion similarly but to a lesser degree than SOX2 knockdown.\",\n      \"method\": \"siRNA knockdown, overexpression, in vitro invasion assay, RT-PCR array of 84 invasion-related genes\",\n      \"journal\": \"Laboratory investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — bidirectional manipulation (KD and OE) with defined downstream mediator (MMP-3), single lab\",\n      \"pmids\": [\"22184093\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Squamous lineage transcription factors p63 and SOX2 transactivate the intronic enhancer cluster of SLC2A1 (GLUT1), driving exceptional glucose influx in squamous cell carcinomas. Elevated glucose influx fuels NADPH/GSH generation and heightens anti-oxidative capacity in SCC tumors.\",\n      \"method\": \"ChIP-seq, luciferase reporter assays for enhancer transactivation, metabolic assays (NADPH/GSH measurement), pharmacologic glucose restriction\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq binding at SLC2A1 enhancer plus functional metabolic phenotype, single lab\",\n      \"pmids\": [\"31412252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TRIM24 activates Sox2 expression at the transcriptional level in glioblastoma cells, as demonstrated by chromatin immunoprecipitation, reporter gene assay, and rescue experiments showing that TRIM24 participation in GBM infiltrative dissemination depends on Sox2.\",\n      \"method\": \"Chromatin immunoprecipitation, reporter gene assay, TRIM24 knockdown, Sox2 rescue experiments, xenotransplantation\",\n      \"journal\": \"Neuro-oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter assay and functional rescue, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"32492707\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Oncogenic Sox2 in esophageal squamous cell carcinoma acquires new binding sites when partnered with Klf5, enhances activity of oncogenes such as Stat3, and activates endogenous retroviruses, inducing expression of double-stranded RNA and dependence on the RNA editing enzyme ADAR1.\",\n      \"method\": \"Sox2 ChIP-seq in murine esophageal organoids, epigenetic landscape mapping, ATAC-seq, transgenic carcinoma models\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — comprehensive ChIP-seq + epigenetic + functional analyses in isogenic organoid model spanning normal to cancer, multiple orthogonal methods\",\n      \"pmids\": [\"33972779\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Sox2 and Klf4 are a functional core for pluripotency induction: polycistronic expression of Sox2 and Klf4 alone (without exogenous Oct4) was sufficient to reprogram fibroblasts and neural progenitor cells to iPSCs. Sox2 and Klf4 cooperatively bind across the genome, leading to epigenetic remodeling of pluripotency genes, with stoichiometry of the two factors being essential.\",\n      \"method\": \"iPSC reprogramming assays, ChIP-seq, epigenetic analysis, genome-wide co-binding\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional reprogramming with ChIP-seq genome-wide co-binding, clear epistasis placing Sox2-Klf4 as core; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"31722212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In mouse E3.5 inner cell mass, SOX2 occupies preaccessible enhancers (opened by early TFs TFAP2C and NR5A2) rather than opening global enhancers, then widely redistributes to open new enhancers or poise them for future activation as cells adopt naive and formative pluripotency states.\",\n      \"method\": \"SOX2 ChIP-seq in mouse embryos from E3.5 to E7.5, ATAC-seq, genetic ablation\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide binding mapped in vivo in embryos across developmental stages with chromatin accessibility, multiple methods\",\n      \"pmids\": [\"38096290\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In mouse ES cells, two DNase I hypersensitive sites (DHSs) in the distal Sox2 enhancer cluster are each individually sufficient for long-range activation of Sox2 expression, requiring only a handful of key TF recognition sequences. Three nearby DHSs are context-dependent, showing no activity alone but augmenting the activity of the autonomous DHSs.\",\n      \"method\": \"Large-scale endogenous locus engineering (Big-IN), scarless DHS deletions/rearrangements/inversions, surgical TF motif alterations, multiple mESC clone analysis\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct endogenous locus manipulation with multiple independent clones, multiple structural perturbations with defined readouts\",\n      \"pmids\": [\"36931273\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Acute depletion of SOX2 results in rapid loss of thousands of accessible chromatin sites within one hour, demonstrating SOX2's role as a pioneer factor maintaining chromatin accessibility. Open chromatin sites maintained by SOX2 are highly predictive of gene expression, while other SOX2 binding sites are largely dispensable for gene regulation.\",\n      \"method\": \"Acute protein depletion, ATAC-seq, nascent transcription analysis, CRISPR-Cas9 regulatory element validation at Klf2 locus\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — acute depletion with rapid chromatin dynamics plus nascent transcription and CRISPR validation, multiple orthogonal methods in single study\",\n      \"pmids\": [\"37691488\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"DNA and nucleosome binding by SOX2 induces major rearrangements in the conformational ensemble of SOX2's intrinsically disordered C-terminal region (IDR), redistributing interdomain interactions and variably exposing two activation domains critical for transcription. The IDR dynamics are guided by weak and dynamic charge interactions with the folded HMG DNA-binding domain.\",\n      \"method\": \"Single-molecule FRET, NMR spectroscopy, molecular simulations\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — single-molecule FRET and NMR with molecular simulations revealing structural mechanism, multiple orthogonal biophysical methods in single study\",\n      \"pmids\": [\"38365983\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Small endogenous fluctuations of SOX2 and OCT4 protein levels in G1 (but not S phase) bias ES cell fate commitment. High OCT4 levels increased chromatin accessibility at differentiation-associated enhancers as measured by ATAC-seq on cells gated for different endogenous factor levels.\",\n      \"method\": \"Knock-in reporter fusion ES cell lines, FACS-gated ATAC-seq, directed differentiation assays\",\n      \"journal\": \"Molecular systems biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — endogenous reporters with ATAC-seq at defined protein levels, single lab with orthogonal methods\",\n      \"pmids\": [\"31556488\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Sox2 activated proliferation of respiratory epithelial cells in vivo, associated with increased cyclin D1, and activated transcription of FoxM1 in vitro. Sox2 also induced ectopic differentiation of alveolar epithelial cells to those with morphologic and molecular characteristics of conducting airway epithelium.\",\n      \"method\": \"Conditional transgenic mouse overexpression, cell cycle gene expression analysis, in vitro transcription assays\",\n      \"journal\": \"American journal of respiratory cell and molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional in vivo overexpression with defined phenotypic and molecular readouts plus in vitro transcription assay, single lab\",\n      \"pmids\": [\"20855650\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"SOX2 is required for inner ear neurogenesis: conditional SOX2 deletion at otocyst stages caused near-absence of NEUROG1-expressing neuroblasts, increased cell death in the neurosensory epithelium, and significantly reduced cochleovestibular ganglion volume. Heterozygotes showed milder neurogenesis reduction, indicating SOX2 dosage-dependence.\",\n      \"method\": \"Conditional knockout mice (Cre-lox), immunofluorescence, fate-mapping experiments\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO in vivo with defined cellular and molecular phenotypes including NEUROG1 expression, dosage relationship confirmed in heterozygotes\",\n      \"pmids\": [\"28642583\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Sox2 directly controls fibronectin fibrillogenesis in Schwann cells, providing a highly oriented fibronectin matrix that supports their organization and directional migration. Sox2 also regulates extracellular matrix and migration genes and formation of focal adhesions, and Sox2-dependent fibronectin matrix is required for neuron migration along oriented Schwann cells.\",\n      \"method\": \"Sox2 overexpression/knockdown in RSC96 line, fibronectin matrix imaging, migration assays, co-culture with neurons, in vivo sciatic nerve regeneration\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — loss/gain-of-function with defined matrix and migration readouts, validated in vivo, single lab\",\n      \"pmids\": [\"32029747\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Conditional deletion of Sox2 from nascent cholinergic amacrine cells in the retina perturbed the normal ratio of cells in the ganglion cell layer versus inner nuclear layer and induced a bistratifying morphology with dendrites distributed to both ON and OFF strata.\",\n      \"method\": \"Conditional knockout mice (Cre-lox), quantitative cell counting, morphological analysis\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with specific cellular phenotype readout (layer positioning and dendritic stratification), single lab\",\n      \"pmids\": [\"25057212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"SOX2 ablation in dermal papilla (DP) cells of hair follicles causes a phenotypic switch from eumelanin to pheomelanin production. Mechanistically, Sox2 directly regulates Agouti (temporal upregulation) and Corin (downregulation) in DP, and BMP signaling regulation by Sox2 downregulates MC1R, Dct, and Tyr in melanocytes.\",\n      \"method\": \"Conditional Sox2 knockout in DP using Lepr-Cre, pigmentation analysis, gene expression, BMP signaling assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with defined molecular pathway (Sox2→Agouti/Corin→BMP→melanocyte genes), single lab\",\n      \"pmids\": [\"35858560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In esophageal squamous cell carcinoma, elevated Sox2 signaling causes endothelial-mesenchymal transitions (EndMTs) by interacting with JMJD5, inducing EndMTs in cerebral endothelial cells. EC-specific suppression of Sox2 normalized endothelial differentiation and lumen formation, improving cerebral AVMs.\",\n      \"method\": \"Conditional Sox2 overexpression/suppression, co-immunoprecipitation, epigenetic profiling, ChIP-seq for JMJD5 as Sox2 target\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP showing Sox2-JMJD5 interaction, ChIP identifying JMJD5 as direct target, functional EC-specific conditional mouse model\",\n      \"pmids\": [\"31232700\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CRISPR-mediated SOX2 deletion in castration-resistant prostate cancer cells reveals that SOX2 promotes metabolic reprogramming including increased glycolysis, glycolytic capacity, basal/maximal oxidative respiration, and spare respiratory capacity. SOX2 ChIP-seq identified prostate-specific target genes (CERK, ECHS1, HS6SDT1, LPCAT4, PFKP, SLC16A3, SLC46A1, TST) distinct from canonical embryonic SOX2 targets.\",\n      \"method\": \"CRISPR KO, Seahorse metabolic assays, SOX2 ChIP-seq, metabolomics\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR KO with multiple orthogonal metabolic readouts and genome-wide binding data, comprehensive single study\",\n      \"pmids\": [\"35067686\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In lung cancer cells, SOX2 bound the EPCAM promoter to induce EpCAM-p21Cip1-cyclin A2 signaling promoting cell proliferation, while SOX9 bound the SLUG promoter for invasion. Ectopic SOX2 expression inhibited SOX9 with increased H3K9me2 on the SOX9 promoter, establishing an epigenetic switch between SOX2 and SOX9 controlling cancer cell plasticity.\",\n      \"method\": \"ChIP, promoter binding assays, HDAC inhibition, ectopic expression, histone methylation analysis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — ChIP at specific promoters plus functional and epigenetic assays, single lab\",\n      \"pmids\": [\"27758880\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"DYRK1A promotes differentiation of glioblastoma stem cells by deactivating CDK5, which results in decreased SOX2 expression. The DYRK1A-CDK5-SOX2 pathway represents a regulatory axis controlling GSC stemness; DYRK1A inhibition insulates self-renewing GSCs from differentiation by maintaining CDK5 activity and SOX2 levels.\",\n      \"method\": \"DYRK1A inhibition/activation, CDK5 knockdown, SOX2 expression analysis, GSC differentiation assays\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — pathway epistasis established by sequential kinase inhibition with defined SOX2 expression readout, single lab\",\n      \"pmids\": [\"33924599\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PSMD7 (a deubiquitinating enzyme) deubiquitinates and stabilizes SOX2 protein in pancreatic cancer cells, increasing SOX2 protein levels and subsequently activating Notch1 signaling. Restoration of SOX2 expression abrogated the antitumor effect of PSMD7 knockdown.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, PSMD7 knockdown, SOX2 rescue experiments, in vivo tumor assays\",\n      \"journal\": \"Cell & bioscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — co-IP plus ubiquitination assays and rescue experiments, single lab\",\n      \"pmids\": [\"38494478\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"miR-126 inhibits SOX2 expression by targeting two binding sites in the 3'-UTR of SOX2 mRNA. Luciferase assays and gain/loss-of-function experiments confirmed this post-transcriptional repression. SOX2 overexpression was found to downregulate PLAC1, identifying PLAC1 as a downstream target of SOX2.\",\n      \"method\": \"Luciferase reporter assays (3'-UTR), miRNA gain/loss-of-function, siRNA knockdown, microarray after SOX2 overexpression\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — direct UTR binding demonstrated by reporter assay plus downstream target identification by microarray, single lab\",\n      \"pmids\": [\"21304604\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Sox2 interferes with Wnt signaling in tooth development by binding to β-catenin; Sox2 knockdown results in failure of cell migration from molar 1 to molar 2, and degradation of Wnt signaling caused by Sox2 knockdown results in lack of cell migration.\",\n      \"method\": \"Temporal Sox2 knockdown, DiI cell tracking assay, Wnt signaling analysis\",\n      \"journal\": \"Cell and tissue research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — direct β-catenin binding (co-IP) plus functional migration tracking, single lab\",\n      \"pmids\": [\"26846112\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SOX2 expression in bladder cancer induces IGF2 expression (gene expression profiling), and SOX2-mediated spheroid formation under low-serum stress is inhibited by pharmacologic inhibition of AKT (MK2206) or IGF1R (linsitinib), placing IGF2-IGF1R-AKT downstream of SOX2.\",\n      \"method\": \"SOX2 overexpression/silencing, gene expression profiling, pharmacologic AKT and IGF1R inhibition, spheroid formation assays\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — pathway placement by pharmacologic inhibition and expression profiling without direct binding or ChIP evidence for IGF2 as direct SOX2 target\",\n      \"pmids\": [\"32427884\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"SOX2 targets acinar-specific genes and is essential for the survival of acinar but not ductal cells during salivary gland development. Genetic ablation of SOX2 results in failure to establish acini. Parasympathetic nerves regulate acinar cell generation via regulation of SOX2.\",\n      \"method\": \"Conditional SOX2 knockout, ChIP-seq for SOX2 target genes in salivary gland, genetic lineage tracing\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with specific acinar/ductal phenotype plus ChIP-seq for acinar targets and nerve-mediated regulation, single lab multiple methods\",\n      \"pmids\": [\"28623666\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SOX2 is a pioneer transcription factor with an HMG DNA-binding domain that directly binds and distorts nucleosomal DNA to facilitate chromatin opening, and also binds RNA via a C-terminal motif to form ternary RNA/SOX2/DNA complexes; its transcriptional activity as an activator is context-dependent on partner factors (OCT4/KLF4 in pluripotency, p63 in squamous cancers), its protein stability is regulated by opposing ubiquitin ligase (CUL4A-DET1-COP1, UBE2S) and deubiquitylase (OTUD7B, PSMD7) activities, its nuclear localization and phosphorylation are controlled by CDK1 and AKT kinase signaling, and it executes tissue-specific roles in stem cell maintenance, lineage specification, and metabolic reprogramming by binding distinct genomic targets across different cell types.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SOX2 is an HMG-domain pioneer transcription factor that binds and locally distorts nucleosomal DNA to control chromatin accessibility, lineage specification, and stem-cell maintenance across diverse tissues [#0, #22]. Cryo-EM shows SOX2 engages nucleosomal DNA at superhelical location 2, detaches terminal DNA from the histone octamer, and repositions the histone H4 N-terminal tail to increase accessibility [#0], and acute SOX2 depletion collapses thousands of accessible chromatin sites within an hour, with the subset it maintains being highly predictive of gene expression [#22]. In pluripotency it cooperates with partner factors: OCT4-SOX2 differentially distort nucleosomal DNA depending on motif placement [#1], SOX2 and KLF4 form a functional reprogramming core that co-binds the genome and remodels pluripotency enhancers [#19], and during early embryogenesis SOX2 first occupies pre-accessible enhancers opened by other factors before redistributing to open or poise new enhancers [#20]. SOX2 functions principally as a transcriptional activator, since substituting a VP16 activation domain enhances reprogramming while a repressor fusion abolishes it [#12], and its intrinsically disordered C-terminal region rearranges upon DNA/nucleosome binding to expose two activation domains [#23]. Beyond DNA, SOX2 binds double-stranded RNA via an HMG-box-associated RNA-binding motif, forming ternary RNA/SOX2/DNA complexes whose disruption impairs reprogramming [#2, #3]. SOX2 partner usage is context-dependent in cancer: it switches from OCT4 to p63 in squamous carcinomas to co-occupy loci and drive oncogenes such as ETV4 [#5], partners with KLF5 to acquire new binding sites and activate endogenous retroviruses [#18], and represses the Hippo activators NF2 and WWC1 to potentiate YAP [#4, #13]. It also reprograms metabolism, transactivating the SLC2A1/GLUT1 enhancer with p63 to fuel glucose influx and antioxidant capacity in squamous tumors [#16] and driving prostate-specific metabolic target genes [#31]. SOX2 protein stability is set by opposing ubiquitin enzymes—UBE2S-mediated K11 ubiquitination at K123 and the CUL4A-DET1-COP1 ligase promote degradation, while deubiquitylases OTUD7B and PSMD7 stabilize it [#7, #8, #34]—and its nuclear localization and activity are controlled by CDK1 and AKT signaling [#6, #9]. Developmentally, SOX2 is required dosage-dependently for inner-ear neurogenesis [#26], salivary acinar cell survival [#38], and lens/nasal placode induction with Oct-1 [#10], while acting as a context-dependent tumor suppressor that restrains Wnt-driven gastric adenoma [#14].\",\n  \"teleology\": [\n    {\n      \"year\": 2006,\n      \"claim\": \"Established that SOX2 acts combinatorially with a POU partner to drive a defined developmental enhancer, framing its activity as context-dependent and partner-driven rather than autonomous.\",\n      \"evidence\": \"Genetic epistasis in double-mutant mice plus in vitro transactivation and transgenic enhancer assays at the Pax6 lens enhancer with Oct-1\",\n      \"pmids\": [\"17140559\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve nucleosome-level binding mechanism\", \"Limited to lens/nasal placode context\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showed SOX2 switches its transcription-factor partner in a tissue-specific manner, explaining how the same factor produces different transcriptional outputs in pluripotency versus cancer.\",\n      \"evidence\": \"ChIP-seq, co-IP and siRNA knockdown in squamous cell carcinoma defining SOX2-p63 co-occupancy and ETV4 dependence\",\n      \"pmids\": [\"24590290\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define structural basis of partner selection\", \"Generality across other SCC subtypes not fully mapped\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined SOX2 as a transcriptional activator that establishes de novo enhancers during reprogramming, distinguishing activation from repression as the functionally relevant output.\",\n      \"evidence\": \"VP16/HP1 activation/repression domain swaps with reprogramming efficiency assays and ChIP-seq\",\n      \"pmids\": [\"28813671\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of de novo enhancer selection not resolved\", \"Did not address chromatin-opening kinetics\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Resolved at near-atomic detail how SOX2 acts as a pioneer factor, showing it distorts nucleosomal DNA and detaches terminal DNA to increase accessibility, alone and with OCT4.\",\n      \"evidence\": \"Cryo-EM structures of SOX2 and OCT4-SOX2 bound to nucleosomes\",\n      \"pmids\": [\"32350470\", \"32327602\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Static structures do not capture chromatin-opening dynamics in cells\", \"Role of partner stoichiometry in vivo unaddressed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Revealed an unexpected RNA-binding function, defining a C-terminal RNA-binding motif that forms ternary RNA/SOX2/DNA complexes and contributes to reprogramming.\",\n      \"evidence\": \"In vitro binding, CLIP and fRIP-seq in ES cells, plus RBM deletion and reprogramming assays\",\n      \"pmids\": [\"32286318\", \"32016422\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of most SOX2-RNA interactions unknown\", \"Whether RNA binding tunes DNA binding in vivo unresolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Connected SOX2 to R-loop biology, showing it inhibits Ddx5 resolvase activity to facilitate reprogramming, linking its nucleic-acid binding to chromatin/genome maintenance.\",\n      \"evidence\": \"Co-IP, R-loop profiling and reprogramming assays with RNaseH1 perturbation\",\n      \"pmids\": [\"32704541\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab co-IP for Sox2-Ddx5 interaction\", \"Direct effect on R-loop structures at SOX2 targets not mapped\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Distinguished functional from incidental SOX2 binding by showing acute depletion rapidly collapses a subset of accessible sites that predict gene expression, defining the productive pioneer activity.\",\n      \"evidence\": \"Acute protein depletion with ATAC-seq, nascent transcription and CRISPR validation\",\n      \"pmids\": [\"37691488\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"What distinguishes productive from dispensable sites mechanistically\", \"Generalizability beyond ES cells\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Mapped SOX2 enhancer logic in vivo and at its own locus, showing it occupies pre-accessible enhancers before redistributing, and that distal autonomous and context-dependent DHSs control its own expression.\",\n      \"evidence\": \"In vivo embryo ChIP-seq/ATAC-seq across stages and endogenous locus engineering (Big-IN) of the Sox2 enhancer cluster\",\n      \"pmids\": [\"38096290\", \"36931273\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Factors directing SOX2 redistribution not fully identified\", \"Enhancer rules may differ in non-embryonic tissues\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Provided the biophysical basis for SOX2 activation, showing DNA/nucleosome binding rearranges the disordered C-terminal region to expose activation domains.\",\n      \"evidence\": \"Single-molecule FRET, NMR and molecular simulations\",\n      \"pmids\": [\"38365983\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether IDR rearrangement recruits specific coactivators unproven\", \"In-cell relevance of conformational ensemble not tested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Consolidated SOX2 as a substrate of opposing ubiquitin/deubiquitin enzymes, establishing post-translational stability control as a major regulatory layer governing its levels in development and cancer.\",\n      \"evidence\": \"Ubiquitination/deubiquitination assays, site-directed mutagenesis (K123), and rescue experiments across ES, NPC and cancer systems (UBE2S, CUL4A-DET1-COP1, OTUD7B, PSMD7)\",\n      \"pmids\": [\"26292759\", \"30405104\", \"38494478\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream signals selecting ligase vs deubiquitylase context unknown\", \"Crosstalk with CDK1/AKT phosphorylation not integrated\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined tissue-specific transcriptional programs and partner-dependent oncogenic functions, from metabolic reprogramming to Hippo/Wnt modulation and squamous ERV activation.\",\n      \"evidence\": \"ChIP-seq, CRISPR KO, metabolic assays and organoid/tumor models across squamous, prostate, gastric and esophageal contexts (p63, KLF5, NF2/WWC1, SLC2A1)\",\n      \"pmids\": [\"31412252\", \"35067686\", \"27498859\", \"33972779\", \"25832504\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How identical HMG domain achieves divergent tissue target selection unresolved\", \"Direct vs indirect status of some metabolic targets not all ChIP-validated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unknown how SOX2 integrates its DNA, RNA, partner-factor, conformational, and post-translational regulatory inputs into a single predictive model of context-specific target selection.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying framework linking partner identity to genomic redistribution\", \"Crosstalk between RNA binding, IDR dynamics and chromatin opening unmapped\", \"Signaling-to-stability-to-localization axis not reconstituted\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 1, 22]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [12, 5, 14]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [2, 3]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [6, 9]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [0, 22]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [9]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [12, 5, 14]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [0, 22, 20]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [10, 26, 38]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [5, 18, 31]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [7, 8, 34]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"POU5F1\", \"KLF4\", \"TP63\", \"KLF5\", \"POU2F1\", \"DDX5\", \"COP1\", \"OTUD7B\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":9,"faith_pct":100.0}}